NAA10 and breast cancer: Example Chip-Seq experiments from ENCOCE showing the strong binding of NRF1 to the promoter of NAA10 but not of NAA20 in MCF7 breast, HepG2 liver and K562 myelogenous leukaemia cell lines are shown in Fig. 4D. One of the established conditions were NRF1 drives the transcription of proteasomal genes is a compensatory response following proteasomal inhibition (Balasubramanian et al. 2012).Based on this we analysed a dataset from human breast cancer MCF-7 cells treated with the MG132 proteasomal inhibitor MG132 for 4 and 24 h (Fig. 4E).